[1] Fujita T, Inoue K, Yamamoto S, et al. ChemInform Abstract: Fungal Metabolites. Part 11. A Potent Immunosuppressive Activity Found in Isaria sinclairii Metabolite[J]. Journal of Antibiotics, 1994,47(2):208-215. [2] Maczis M, Milstien S, Spiegel S. Sphingosine-1-phosphate and estrogen signaling in breast cancer[J]. Advances in Biological Regulation, 2015, 60:160-165. [3] Azuma H, Takahara S, Ichimaru N, et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models[J]. Cancer Research, 2002, 62(5):1410-1419. [4] Mousseau Y, Mollard S, Faucherdurand K, et al. Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model[J]. Breast Cancer Research & Treatment, 2012, 134(1):31-40. [5] Carroll B, Donaldson J C, Obeid L. Sphingolipids in the DNA damage response[J]. Advances in Biological Regulation, 2015,58:38-52. [6] Marvaso G, Barone A, Amodio N, et al. Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.[J]. Cancer Biology & Therapy, 2014, 15(6):797-805. [7] Ohotski J, Rosen H, Bittman R, et al. Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: The role of sphingosine 1-phosphate receptor-[J]. Cellular Signalling,2014, 26(5):1040-1047. [8] Azuma H, Takahara S, Horie S, et al. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment.[J]. Journal of Urology, 2003, 169(6):2372-2377. [9] Rosales K R, Singh G, Wu K, et al. Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins[J]. Biochemical Journal, 2011, 439(2):299-311. [10] Pyne N J, Ohotski J, Bittman R, et al. The role of sphingosine 1-phosphate in inflammation and cancer[J]. Advances in Biological Regulation, 2014, 54:121-129. |